ICICI Direct: Gland Pharma IPO - Investment Rationale
Medicinal tablets are arranged for a photograph in Mumbai. (Photographer: Dhiraj Singh/Bloombergg)

ICICI Direct: Gland Pharma IPO - Investment Rationale


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

ICICI Direct Report

Established in Hyderabad in 1978, Gland Pharma is one of the largest and fastest growing injectable-focused business to business companies, with a global footprint across 60 countries, including the U.S., Europe, Canada, Australia, India and other markets.

It is a niche player in sterile injectables, oncology and ophthalmic solutions with focus on first-to-file, 505(b)(2) filings and NCE- 1s.

Along with its partners Gland has 267 abbreviated new drug application filings (101 owned) in the U.S. as of Q1 FY21, of which 215 were approved.

Click on the attachment to read the full report:

ICICI Direct GlandPharma IPO Review.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Also read: Gland Pharma IPO: All You Need To Know

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.